 
MAINE STATE LEGISLATURE  
 
 
 
The following document is provided by the 
LAW AND LEGISLATIVE DIGITAL LIBRARY  
at the Maine State Law and Legislative Reference Library 
http://legislature.m aine.gov/lawlib 
 
 
 
 
 
 
 
 
 
 
Reproduced from electronic originals 
(may include minor formatting diffe rences from printed original) 
 
 
Printed on recycled paper129th MAINE LEGISLATURE
FIRST REGULAR SESSION-2019
Legislative Document No. 793
S.P. 237 In Senate, February 12, 2019
An Act  To Improve  Accountability  of Opioid Manufacturers
Reference to the Committee on Judiciary  suggested and ordered  printed.
DAREK M.  GRANT
Secretary of the Senate
Presented by President JACKSON of Aroostook.
Cosponsored by Representative MADIGAN of Waterville and
Senators: CLAXTON of Androscoggin, GRATWICK of Penobscot,  LIBBY of Androscoggin, 
VITELLI of Sagadahoc,  Representatives: BAILEY of Saco,  HYMANSON of York.

Page 1 - 129LR1130(01)-11Be it enacted by the People of the State of Maine as follows:
2Sec. 1.  5 MRSA c. 525 is enacted to read:
3CHAPTER 525
4OPIOID CRISIS ACCOUNTABILITY ACT
5§20101.  Short title
6This chapter may be known and cited as "the Opioid Crisis Accountability Act."
7§20102.  Definitions
8As used in this chapter, unless the context otherwise indicates, the following terms 
9have the following meanings.
101.  Abuse liability.  "Abuse liability" means the potential of an opioid medication to 
11result in physical or psychological dependence on the opioid medication that is likely to 
12lead to substance use disorder as described in section 20003, subsection 17-A.
132.  Commissioner.  "Commissioner" means the Commissioner of Health and Human 
14Services.
153.  Department.  "Department" means the Department of Health and Human 
16Services.
174.  Opioid medication manufacturer or distributor.  "Opioid medication 
18manufacturer or distributor" means a business operating in this State that manufactures or 
19distributes opioid medication to another person or business in this State.
20§20103.  Illegal marketing or distribution of opioid medication prohibited
211.  Prohibited acts.  An opioid medication manufacturer or distributor may not:
22A.  Falsely represent in this State, by means of distributing marketing materials or 
23otherwise advertising, that an opioid medication:
24(1)  Does not have abuse liability; or
25(2)  Has a lower abuse liability than another opioid medication;
26B.  Distribute a quantity of opioid medications in this State that is not medically 
27reasonable; or
28C.  Fail to report to the commissioner pursuant to section 20104 an order or pattern of 
29orders for the distribution of opioid medication in this State that is not medically 
30reasonable.
Page 2 - 129LR1130(01)-11§20104.  Reporting required
2An opioid medication manufacturer or distributor shall report to the commissioner an 
3order or pattern of orders for the distribution of opioid medication in this State that is not 
4medically reasonable.
5§20105.  Medically reasonable standard
6The department shall establish by rule the medically reasonable standard applicable 
7to section 20103, subsection 1, paragraphs B and C.  In adopting the standard, the 
8department shall consult data from the automated reports and consolidated ordering 
9system of the United States Department of Justice.
10§20106.  Investigation
11The Attorney General, upon the Attorney General's own initiative or upon petition of 
12the commissioner or of 50 or more residents of the State, shall investigate suspected 
13violations of this chapter.
14§20107.  Violations
151.  Penalty for individual.  Notwithstanding any other law to the contrary, a person 
16employed by an opioid medication manufacturer or distributor who directly and 
17knowingly violates section 20103 or 20104 commits a civil violation for which a fine of 
18not more than the total of the following may be adjudged:
19A.  The amount of the person's salary from the period in which the person was in 
20violation; and
21B.  The amount by which the person's stock or other certificates of ownership interest 
22in the opioid medication manufacturer or distributor increased in value during the 
23period in which the person was in violation.
242.  Penalty for business.  An opioid medication manufacturer or distributor that 
25knowingly violates section 20103 or 20104 commits a civil violation for which a fine of 
26not more than 25% of the total profit of the opioid medication manufacturer or distributor 
27from the sale of opioid medication in the United States during the period in which the 
28opioid medication manufacturer or distributor was in violation.
29§20108.  Fund
301.  Fund established.  The Opioid Reimbursement Fund, referred to in this section as 
31"the fund," is established as a nonlapsing fund in the department for the purposes 
32specified in this section.
332.  Source of funds.  The State Controller shall credit to the fund any penalties and 
34fines assessed for violations of this chapter.
353.  Uses of the fund.  The fund may be used for activities of the department relating 
36to substance use disorder pursuant to chapter 521.
Page 3 - 129LR1130(01)-11§20109.  Rules
2The department may adopt rules necessary to implement this chapter. Rules adopted 
3pursuant to this section are routine technical rules as defined in Title 5, chapter 375, 
4subchapter 2-A.
5§20110.  Retroactivity
6This Act applies retroactively to January 1, 1985.
7SUMMARY
8This bill prohibits opioid medication manufacturers and distributors from falsely 
9advertising that an opioid medication does not have abuse liability or has a lower abuse 
10liability than another opioid medication; distributing a quantity of opioid medications that 
11is not medically reasonable; or failing to report orders that are not medically reasonable.  
12It establishes a civil violation and authorizes the Attorney General to investigate 
13violations.  It creates a fund into which the penalties and fees must be paid.  This 
14legislation applies retroactively to January 1, 1985.
